# Emory Alzheimer's Disease Research Center

> **NIH NIH P30** · EMORY UNIVERSITY · 2021 · $468,772

## Abstract

SUMMARY/ABSTRACT: CLINICAL CORE 
The primary goals of the Clinical Core are to support and enhance research efforts of the Goizueta Alzheimer’s 
Disease Research Center (ADRC) at Emory to advance cutting-edge research to identify novel biomarkers and 
therapeutic targets while reducing racial disparities in AD research. The Clinical Core plays a central role in the 
Goizueta ADRC by engaging diverse research participants and driving activities that reflect the Center’s overall 
themes. To accomplish these goals, the Clinical Core has well-established processes to recruit, track, 
characterize, and retain a cohort of longitudinal research participants and to effectively coordinate activities 
and share data with other components of the ADRC and external partners. In the current funding period, the 
Clinical Core established a Longitudinal Biomarker Collection to support high-priority multicenter research 
projects, including the Accelerating Medicine Partnership for AD (AMP-AD) and Molecular Mechanisms of the 
Vascular Etiology of AD (M2OVE-AD). Successful development of the LBC led to a competitive supplement to 
establish a Biomarker Core which will continue as a Core component in the ADRC renewal. Also, during the 
current cycle, we succeeded in our ambitious goal for increasing the diversity of our UDS cohort by enrolling an 
equal number of new African-American and Caucasian participants. This success supported the establishment 
of a Minority Engagement Core (MEC). Specific Aims for this renewal are to 1) Establish and maintain a 
diverse cohort of well-characterized research participants to support priorities in current ADRD research; 2) 
Advance biomarker discovery efforts by harmonizing procedures for sample collection and clinical phenotyping 
across multiple related projects and cohorts; and 3) Expand and integrate activities in ADRD, including 
vascular cognitive impairment and Lewy body diseases. Achieving these Specific Aims will advance the 
priorities identified in the National Alzheimer’s Project Act (NAPA) and recommendations from the NIH ADRD 
Research Summits, and will ultimately lead to effective diagnostic tools and treatments for individuals suffering 
from AD and related disorders.

## Key facts

- **NIH application ID:** 10212229
- **Project number:** 5P30AG066511-02
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** JAMES J LAH
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $468,772
- **Award type:** 5
- **Project period:** 2020-07-15 → 2025-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10212229

## Citation

> US National Institutes of Health, RePORTER application 10212229, Emory Alzheimer's Disease Research Center (5P30AG066511-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10212229. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*